Trial Condition(s):
Atrial Fibrillation
Explore the efficacy and safety of once-daily oral rivaroxaban for the prevention of cardiovascular events in subjects with nonvalvular atrial fibrillation scheduled for cardioversion (X-VERT)
Bayer Identifier:
15693
ClinicalTrials.gov Identifier:
EudraCT Number:
EU CT Number:
Not Available
Trial Purpose
A study for patients with abnormal heart rhythm (atrial fibrillation) who need to undergo cardioversion (procedure to restore normal heart rhythm). The study will compare patients assigned randomly (like flipping a coin) to either Rivaroxaban or vitamin K antagonist (VKA). The study will measure common medical outcomes for this type of patient such as bleeding and stroke.
Inclusion Criteria
- Men or women aged >= 18 years - Hemodynamically stable nonvalvular atrial fibrillation longer than 48 hours or of unknown duration - Scheduled for cardioversion (electrical or pharmacological) of nonvalvular atrial fibrillation - Women of childbearing potential and men must agree to use adequate contraception when sexually active
Exclusion Criteria
- Severe, disabling stroke (modified Rankin score of 4- 5, inclusive) within 3 months or any stroke within 14 days prior to randomization - Transient ischemic attack within 3 days prior to randomization - Acute thromboembolic events or thrombosis (venous/arterial) within the last 14 days prior to randomization - Acute Myocardial infarction (MI) within the last 14 days prior to randomization - Cardiac-related criteria: known presence of cardiac thombus or myxoma or valvular atrial fibrillation - Active bleeding or high risk for bleeding contraindicating anticoagulant therapy - Concomitant medications: indication for anticoagulant therapy other than atrial fibrillation, chronic aspirin therapy > 100 mg daily or dual antiplatelet therapy, strong inhibitors of both cytochrome P450 (CYP) 3A4 and P-glycoprotein (P-gp) if used systemically - Concomitant conditions: childbearing potential without proper contraceptive measures, pregnancy, or breast feeding; hypersensitivity to investigational treatment or comparator treatment; calculated creatinine clearance (CrCl) < 30 mL/minute; hepatic disease which is associated with coagulopathy leading to a clinically relevant bleeding risk; any severe condition that would limit life expectancy to less than 6 months; planned invasive procedure with potential for uncontrolled bleeding; inability to take oral medication; ongoing drug addiction or alcohol abuse - Any other contraindication listed in the local labeling for the comparator treatment or experimental treatment - Participation in a study with an investigational drug or medical device within 30 days prior to randomization
Trial Summary
Enrollment Goal
Trial Dates
Phase
Could I receive a placebo?
Products
Accepts Healthy Volunteers
Where to Participate
| Locations | |
|---|---|
Locations Investigative Site Milano, Italy, 20097 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Catania, Italy, 95126 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Ancona, Italy, 60126 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Como, Italy, 22020 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Bari, Italy, 70021 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Venezi, Italy, 30174 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Torino, Italy, 10126 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Roma, Italy, 00169 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Kuils River, South Africa, 7580 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Worcester, South Africa, 6850 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Bloemfontein, South Africa, 9301 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Cape Town, South Africa, 7450 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site SOWETO, South Africa, 2013 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Somerset West, South Africa, 7130 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Alberton, South Africa, 1449 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Majadahonda, Spain, 28222 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Barcelona, Spain, 08036 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Granada, Spain, 18012 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Pamplona, Spain, 31008 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Sabadell, Spain, 08208 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Heraklion, Greece, 711 10 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Thessaloniki, Greece, 54642 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Alexandroupolis, Greece, 68100 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Attica / Athens, Greece, 11526 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Viborg, Denmark, 8800 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Herning, Denmark, 7400 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Hellerup, Denmark, 2900 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site København NV, Denmark, 2400 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site HEERLEN, Netherlands, 6419 PC | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site MAASTRICHT, Netherlands, 6229 HX | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site LEEUWARDEN, Netherlands, 8934 AD | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Welwyn Garden City, United Kingdom, AL7 4HQ | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site ARNHEM, Netherlands, 6815 AD | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site HAARLEM, Netherlands, 2035 RC | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Frankfurt, Germany, 60596 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Mönchengladbach, Germany, 41063 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Montreal, Canada, H1T 1C8 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Turku, Finland, 20521 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Lappeenranta, Finland | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Pori, Finland, 28500 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Jyväskylä, Finland, 40620 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Oulu, Finland | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Berlin, Germany, 13353 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Edmonton, Canada, T5H 3V9 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site LEUVEN, Belgium, 3000 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Singapore, Singapore, 168752 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Singapore, Singapore, 308433 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Singapore, Singapore, 768828 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Toronto, Canada, M5B 1W8 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Hamilton, Canada, L8L 2X2 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site LILLE, France, 59000 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site ARRAS, France, 62000 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Paris cedex 13, France, 75013 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site TOULOUSE cedex, France, 31059 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site VANDOEUVRE-LES-NANCY, France, 54511 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Vila Nova de Gaia, Portugal, 4434-502 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Lisboa, Portugal, 1169-024 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Almada, Portugal, 2801-951 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Carnaxide, Portugal, 2795-53 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Faro, Portugal, 8000-386 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Sao Martinho do Bispo, Portugal, 3041-801 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Essen, Germany, 45147 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Hamburg, Germany, 20246 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Freiburg, Germany, 79106 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Bad Oeynhausen, Germany, 32545 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Bournemouth, United Kingdom, BH7 7DW | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Portsmouth, United Kingdom, PO6 3LY | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Chesterfield, United Kingdom, S44 5DX | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Leicester, United Kingdom, LE3 9QP | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Nottingham, United Kingdom, NG5 1PB | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Cliftonville, United Kingdom, NN1 5BD | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site London, United Kingdom, SW17 0RE | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Rapid City, United States, 57701 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Lincoln, United States, 68506 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Mobile, United States, 36608 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Tallahassee, United States, 32308 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site BRUXELLES - BRUSSEL, Belgium, 1070 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site HASSELT, Belgium, 3500 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site LIEGE, Belgium, 4000 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site MOL, Belgium, 2400 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site GILLY, Belgium, 6060 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Vaasa, Finland, 65130 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Tampere, Finland, FIN-33520 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Singapore, Singapore, 119228 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Canton, United States, 44710 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Buffalo, United States, 14215 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Miramar, United States, 33025 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Sacramento, United States, 95819 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Doylestown, United States, 18901 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Wausau, United States, 54401 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site National City, United States, 91950 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site El Cajon, United States, 92020 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Madrid, Spain, 28007 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Montreal, Canada, H2W 1T8 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Rockford, United States, 61107 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site New York, United States, 10032 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Dresden, Germany, 01067 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Scottsdale, United States, 85258 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Nürnberg, Germany, 90471 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Leipzig, Germany, 04289 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Toledo, United States, 43623 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Albuquerque, United States, 87102 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Stamford, United States, 06905 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Butler, United States, 16001 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Helsinki, Finland, FIN-00260 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Victoria, Canada, V8R 4R2 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Layton, United States, 84041 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Cleveland, United States, 44195 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Tyler, United States, 75701 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Clearwater, United States, 33756 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Deltona, United States, 32725 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Ft. Lauderdale, United States, 33316 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Bridgewater, United States, 08807 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Daytona Beach, United States, 32117 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Fort Sam Houston, United States, 78234-6200 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Wilmington, United States, 19803 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Philadelphia, United States, 19141 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Hershey, United States, 17033 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Annapolis, United States, 21401 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Beijing, China, 100029 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Xi'an, China, 710061 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Orlando, United States, 32806 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Shenyang, China, 110016 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Wuhan, China | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Urumqi, China, 830054 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Guangzhou, China, 510080 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Nanchang, China, 330006 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Changchun, China, 130021 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Torrance, United States, 90502 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Troy, United States, 12180 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Manalapan, United States, 07716 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Austin, United States, 78745 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site New Haven, United States, 06520 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Melbourne, United States, 32901 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site St. Augustine, United States, 32086 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Jacksonville, United States, 32216 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Joliet, United States, 60435 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site TOURS, France, 37044 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site PARIS, France, 75012 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Mainz, Germany, 55131 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site St. John's, Canada, A1B 3V6 | Contact Us: E-mail: [email protected] Phone: Not Available |
Trial Design
A prospective, randomized, open-label, parallel-group, active-controlled, multicenter study exploring the efficacy and safety of once-daily oral rivaroxaban (BAY59-7939) compared with that of dose-adjusted oral vitamin K antagonists (VKA) for the prevention of cardiovascular events in subjects with nonvalvular atrial fibrillation scheduled for cardioversion
Trial Type:
Interventional
Intervention Type:
Drug
Trial Purpose:
Prevention
Allocation:
Randomized
Blinding:
Open Label
Assignment:
Parallel Assignment
Trial Arms:
2
Primary Outcome
- Number of participants with composite of the following events, adjudicated centrally: stroke, transient ischemic attack, non-central nervous system systemic embolism, myocardial infarction and cardiovascular deathStroke, TIA, Non-CNS Embolism, MI and cardiovascular death were adjudicated and confirmed by Clinical Endpoints Committee (CEC). Stroke included hemorrhagic and ischemic infarction. TIA including information if with or without matching lesion. Non CNS systemic embolism included emboli in peripheral arterial of the upper and lower extremities, ocular and retinal (pulmonary embolism and MI were excluded from the category). MI was assessed based on either cardiac biomarkers, new abnormal Q waves appeared on electrocardiogram for >= 2 leads, or autopsy confirmation. Cardiovascular death included death in subjects with non-valvular atrial fibrillation (AF). Number of subjects with composite events were reported.Timeframe: From randomization to the date of last dose of study drug +2 days for subjects who completed planned treatment or the earlier date [last planned dose, follow-up visit at the end of 30-day follow-up period] for subjects who prematurely stopped treatment
- Number of participants with major bleedings as per central adjudicationBleeding events were adjudicated and confirmed by CEC blinded to treatment. The CEC categorized the bleeding events as major or non-major. The bleeding events were defined per the International Society on Thrombosis and Hemostasis (ISTH) criteria. Major bleeding was clinically overt bleeding associated with a fall in hemoglobin of 2 gram per deciliter (g/dL) or higher, leading to a transfusion of 2 or more units of packed red blood cells or whole blood, occurring in a critical site or contributing to death. Number of subjects with confirmed adjudicated bleeding events occurring in greater than (>)1 total subjects were reported.Timeframe: From randomization up to the date of the last dose of study drug + 2 days
Secondary Outcome
- Number of participants with composite of strokes and non-central nervous system systemic embolismsStroke and Non-CNS Embolism were adjudicated and confirmed by CEC. Stroke included hemorrhagic and ischemic infarction. Non CNS systemic embolism included emboli in peripheral arterial of the upper and lower extremities, ocular and retinal (pulmonary embolism and MI were excluded from the category). Number of subjects with composite events were reported.Timeframe: From randomization to the date of last dose of study drug +2 days for subjects who completed planned treatment or the earlier date [last planned dose, follow-up visit at the end of 30-day follow-up period] for subjects who prematurely stopped treatment
- Number of participants with composite of strokes, transient ischemic attacks, non-central nervous system systemic embolisms, myocardial infarctions and all-cause mortalityStroke, TIA, Non- CNS systemic embolism, MI and all-cause mortality were adjudicated and confirmed by CEC. Stroke included hemorrhagic and ischemic infarction. TIA including information if with or without matching lesion. Non CNS systemic embolism included emboli in peripheral arterial of the upper and lower extremities, ocular and retinal (pulmonary embolism and MI were excluded from the category). MI was assessed based on either cardiac biomarkers, new abnormal Q waves appeared on electrocardiogram for >= 2 leads, or autopsy confirmation. All-cause mortality included vascular death and non-vascular death. Number of subjects with composite events were reported.Timeframe: From randomization to the date of last dose of study drug +2 days for subjects who completed planned treatment or the earlier date [last planned dose, follow-up visit at the end of 30-day follow-up period] for subjects who prematurely stopped treatment
- Number of participants with strokesAll events were adjudicated and confirmed by a CEC blinded to treatment. Stroke included hemorrhagic (Stroke with local collections of intraparenchymal blood. Subarachnoid hemorrhage, subdural hemorrhage, and epidural hemorrhage were excluded), ischemic infarction (Stroke without focal collection of intracranial blood) and unknown (No imaging data and anatomic findings were available). Number of subjects with strokes were reported.Timeframe: From randomization to the date of last dose of study drug +2 days for subjects who completed planned treatment or the earlier date [last planned dose, follow-up visit at the end of 30-day follow-up period] for subjects who prematurely stopped treatment
- Number of participants with transient ischemic attacksAll events were adjudicated and confirmed by a CEC blinded to treatment. Number of subjects with TIA were reported.Timeframe: From randomization to the date of last dose of study drug +2 days for subjects who completed planned treatment or the earlier date [last planned dose, follow-up visit at the end of 30-day follow-up period] for subjects who prematurely stopped treatment
- Number of participants with non-central nervous system systemic embolismsAll events were adjudicated and confirmed by a CEC blinded to treatment. Non CNS systemic embolism included emboli in peripheral arterial of the upper and lower extremities, ocular and retinal (pulmonary embolism and MI were excluded from the category). Number of subjects with non-CNS embolism were reported.Timeframe: From randomization to the date of last dose of study drug +2 days for subjects who completed planned treatment or the earlier date [last planned dose, follow-up visit at the end of 30-day follow-up period] for subjects who prematurely stopped treatment
- Number of participants with myocardial infarctionsAll events were adjudicated and confirmed by a CEC blinded to treatment. MI was assessed based onmeither cardiac biomarkers, new abnormal Q waves appeared on electrocardiogram for >= 2 leads, or autopsy confirmation. Number of subjects with MI were reported.Timeframe: From randomization to the date of last dose of study drug +2 days for subjects who completed planned treatment or the earlier date [last planned dose, follow-up visit at the end of 30-day follow-up period] for subjects who prematurely stopped treatment
- Number of participants with cardiovascular deathsAll events were adjudicated and confirmed by a CEC blinded to treatment. Any death that was not clearly non-vascular (e.g., deaths due to spontaneous bleeding, myocardial infarction, stroke, cardiac failure, and arrhythmia). Number of subjects with cardiovascular deaths were reported.Timeframe: From randomization to the date of last dose of study drug +2 days for subjects who completed planned treatment or the earlier date [last planned dose, follow-up visit at the end of 30-day follow-up period] for subjects who prematurely stopped treatment
- Number of participants with all-cause mortalityAll events were adjudicated and confirmed by a CEC blinded to treatment. All-cause mortality included vascular death and non-vascular death. Number of subjects with all-cause mortality were reported.Timeframe: From randomization to the date of last dose of study drug +2 days for subjects who completed planned treatment or the earlier date [last planned dose, follow-up visit at the end of 30-day follow-up period] for subjects who prematurely stopped treatment
- Number of participants with composite of major and non-major bleeding eventsAll events were adjudicated and confirmed by a CEC blinded to treatment. The CEC categorized the bleeding events as major or non-major. The bleeding events were defined per the ISTH criteria. Clinically relevant bleeding included major bleeding (overt bleeding associated with 2 g/dL or greater fall in hemoglobin, leading to a transfusion of 2 or more units of packed red blood cells or whole blood, occurring in a critical site or contributing to death) and non-major bleeding associated with medical intervention, unscheduled physician contact, (temporary) cessation of study treatment, discomfort for the participants such as pain, or impairment of activities of daily life. Number of subjects with clinically relevant major and non-major bleeding events were reported.Timeframe: From randomization up to the date of the last dose of study drug + 2 days
Additional Information
Copyright © Bayer
Powered by
